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ABSTRACT
Background: The aim of this meta-analysis was to compare the impact of transcatheter aortic 
valve implantation (TAVI) vs. surgical aortic valve replacement (SAVR) in patients with severe 
aortic valve stenosis at low surgical risk.
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Methods: All randomized controlled trials (RCTs) and observational studies (Obs) published from 
January 2014 until March 31st, 2020 were retrieved through the PubMed computerized database 
and at the site https://www.clinicaltrials.com. The relative risk (RR) with the 95% confidence 
interval (CI) was used to evaluate the effect of the intervention under comparison. The primary 
endpoints were all-cause 30-day mortality and 1-year mortality. The 30-day safety endpoints were: 
stroke, acute kidney injury stage 2 or 3, major bleeding, moderate/severe paravalvular leak, need 
for new permanent pacemaker (PM) implantation.
Results: After detailed review 9 studies, related to 4 RCTs and 5 Obs, were selected. The overall 
analysis of RCTs plus Obs showed a significantly lower 30-day mortality for TAVI (RR = 0.55; 
95% CI 0.45–0.68, p < 0.00001; I2 = 0%). However, an increased risk of new PM implantation (RR
= 2.87; 95% CI 2.01–3.67, p < 0.00001, I2 = 0%) and of paravalvular leak (RR = 7.28; 95% CI 
3.83–13.81, p < 0.00001, I2 = 0%) was observed in TAVI compared to SAVR. On the contrary, a 
lower incidence of major bleeding (RR = 0.38; 95% CI 0.27–0.54, p < 0.00001, I2 = 0%) and of 
acute kidney injury was observed (RR = 0.33; 95% CI 0.19–0.56, p < 0.0001, I2 = 0%) in TAVI.
Conclusions: TAVI and SVAR in the treatment of AS in the patients at low surgical risk are not 
superimposable. In particular, if 30-day and 1-year mortality, major bleeding and acute kidney 
injury were significantly lower for TAVI, the need of new PM implantation and paravalvular leak 
were significantly lower in SAVR. Consequently, we suggest the need of more trials to evaluate the
effectiveness of TAVI as routine therapeutic procedure in the treatment of patients with low 
surgical risk AS.
Key words: transcatheter aortic valve interventions, transcatheter aortic valve implantation, 
aortic stenosis, prosthetic aortic valves, low surgical risk, meta-analysis
INTRODUCTION
Surgical aortic valve replacement (SAVR) had been the only effective therapy for patients 
with aortic stenosis (AS) until the introduction into clinical practice of transcatheter aortic valve 
implantation (TAVI). The remarkable advances in bioengineering technology and interventional 
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cardiology techniques over the years have benefited from the following issues: (i) a drastic 
reduction in mortality rates, (ii) a significant reduction of complications, due to better patient 
selection and preprocedural computerized tomography, and (iii) greater operator experience. The 
robust evidence in favor of TAVI resulting from randomized controlled trials (RCTs) were 
summarized in the international guidelines [1, 2] that strongly recommend TAVI in inoperable, 
high- or intermediate-risk patients. Recently, on the basis of RCTs and registries, TAVI was 
successfully reported in patients with intermediate and low surgical risk with comparable or even 
better results than SAVR [3–14]. Moreover in 2019, PARTNER 3 and EVOLUT LOW RISK trials, 
performed on patients with severe AS at low risk of death with surgery, demonstrated benefits of 
TAVI over surgery [9, 11]. As a consequence, recently the United States Food and Drug 
Administration (FDA) first approved an expanded indications for several transcatheter heart valves 
(the Edwards Lifesciences’s Sapien 3 and Sapien 3 Ultra, and self-expanding Medtronic CoreValve
Evolut R and CoreValve Evolut PRO) including patients who are at low surgical risk for death or 
major complications associated with open-heart surgery (https://www.fda.gov/news-events/press-
announcements/fda-expands-indication-several-transcatheter-heart-valves-patients-low-risk-death-
or-major. Accessed May 14, 2020). Indeed, on the basis of the results of PARTNER 3 trial, 
Edwards Lifesciences announced that SAPIEN 3 valve cleared for use in low-risk patients in 
Europe (https://www.edwards.com/ns20191106. Accessed May 14, 2020). As encouraging data 
continue to emerge, TAVI seems destined to replace SAVR as the gold standard therapy of AS [15, 
16].
Based on the previous evidence, the aim of our meta-analysis of RCTs and observational 
studies (Obs) was to compare TAVI vs SAVR in patients with AS at low surgical risk.
METHODS
The present meta-analysis was performed in accordance with the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) statement. The literature search was 
performed through PubMed and Cochrane computerized database and at the site 
https://clinicaltrials.gov , in order to include all studies published between January 2014 to March 
31st, 2020 reporting on TAVI vs. trans-vascular SAVR in patients with severe AS at low surgical 
risk. The low-risk population was defined by STS score < 4% (Society of Thoracic Surgeons 
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Predicted Risk of Mortality [STS-PROM]) or Logistic (European System of Cardiac Operative 
Risk Evaluation [LES]) Euroscore < 10%) [17–19]. The reference lists of retrieved full-text articles
were also examined to identify potentially relevant studies not selected by the electronic search.
Two investigators independently performed the studies selection with the aim to include 
only studies that reported 30-day and/or at least one of the safety endpoints under evaluation. 
Conflicts were resolved by consulting a third investigator.
Studies published in languages other than English, conference abstracts or proceedings, 
TAVI performed using transapical approach, SAVR performed with sutureless prostheses and 
duplicate studies, were excluded from the meta-analysis. 
Outcomes
The primary endpoints were all-cause 30-day mortality and 1-year mortality. The 30-day 
safety endpoints were: the need for new permanent pacemaker (PM) implantation, major bleeding 
(including major, life threatening, or disabling bleeding), acute kidney injury stage 2 or 3, stroke, 
moderate/severe paravalvular leak. Endpoint criteria were selected according to the standardized 
definitions of the Valve Academic Research Consortium (VARC)-2 [20].
Statistical analysis
The meta-analysis was performed using Review Manager (RevMan) (computer program) 
Version 5.3. (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) [21]. 
The relative risks (RR) with the 95% confidence intervals (CI) were computed for each individual 
study, and RRs were combined using the Mantel-Haenszel random-effect model to take into 
account possible heterogeneity among studies rather than chance. A Forest plot was used for a 
graphical presentation of the results (reporting the effect estimates for the individual studies 
together with the overall measure of effect) and the selected studies were examined to assess the 
homogeneity/heterogeneity of the results by visually inspecting the overlap of the CIs of the risk 
estimates in the different studies and by computing the Cochran Q test and I2 statistics.  The meta-
analysis was performed taking into account RCTs and Obs subgroups, using the test for subgroup 
differences to evaluate the agreement/disagreement of the results between RCTs and Obs. In case 
of heterogeneity greater than moderate into each subgroup (i.e., I2 > 60%) [22] a funnel plot 
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together with the 95% confidence limits around the summary treatment effect (i.e.: the expected 
distribution of studies in the absence of heterogeneity or of selection biases) [23] was drawn and a 
sensitivity analysis was performed by excluding the studies falling outside the 95% CI at the visual 
inspection of the Funnel plot. 
All statistical tests were two sided and alpha (α) error of ≤ 0.05 was defined as statistically 
significant.
RESULTS
After detailed review, 9 studies related to 4 RCTs [4, 5, 8–11, 13] and 5 Obs [14, 24–28] out
of 5946 articles were selected (Fig. 1). The main characteristics of the selected studies are reported 
in Table 1.
Primary endpoints 
30-day mortality was reported in 8 of the 9 selected studies and were assessed in 26,989 
patients (2629 from 3 RCTs, 24,360 from 5 Obs) [5, 9, 11, 14, 24–27], occurred in 1.6% of TAVI 
compared to 2.7% of SAVR. Indeed, the study by Serruys et al. [13] on SURTAVI subgroup with 
STS < 3 reports only 1-year mortality. The overall analysis showed a non-significant risk reduction 
in TAVI compared to SAVR (RR = –36%, p = 0.11); the analysis by subgroups showed in RCTs a 
significant risk reduction in favor of TAVI (RR = –56%, p = 0.04) while, in Obs the reduction of 
deaths in favor of TAVI was not significant (RR = –25%, p = 0.51) (Fig. 2). Indeed, the RCTs 
showed homogeneous results (I2 = 0%), whereas Obs were affected by high heterogeneity (I2 = 
67%) (Fig. 2A). The visual inspection of the Forest plot detected in the study by Schaefer et al. [25]
indicated the potential source of bias: it was the only study with a RR significantly in favor of 
SAVR (RR = 3.56, with a 95% CI ranging from 1.22 to 10.42; Fig. 2A). At the Funnel plot, the 
larger studies were plotted at the central top of the graph, demonstrating a convergence in the risk 
estimation with the increase of the sample size, whereas the smaller studies were scattered at the 
bottom of the graph. Again, the study of Schaefer et al. [25] was the only one falling outside the 
95% CI. In the sensitivity analysis, by excluding the study by Schaefer et al. [25], the reduction in 
30-day mortality in TAVI became significant also in the overall analysis (RR = –45%, p < 0.00001)
and in Obs (RR = –44%, p < 0.00001) in absence of heterogeneity (I2 = 0%) (Fig. 2B). The test for 
subgroup difference showed agreement between RCTs and Obs (Chi2 = 0.31, df = 1, p = 0.58, I2 = 
0%; Fig. 2B). 
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1-year mortality, was assessed in 22,701 patients (2883 from 4 RCTs, 19818 from 2 Obs) 
[5, 9, 11, 13, 14, 25]. The overall analysis showed a non-significant risk reduction in TAVI 
compared to SAVR (RR = –24%, p = 0.16); the analysis by subgroups showed in RCTs a 
significant risk reduction in favor of TAVI (RR = –38%, p = 0.04) whereas in Obs  non-significant 
risk increases in TAVI were observed (RR = +2%, p = 0.93; Fig. 3). The results among the 4 RCTs 
were homogeneous (I2 = 0%); a slight heterogeneity affected the two Obs (I2 = 25%). On the 
contrary, a high heterogeneity between RCTs and Obs was demonstrated in the test for subgroup 
differences (Chi2 = 2.87, df = 1, p = 0.09, I2 = 65.1%; Fig. 3).
Safety endpoints
Permanent pacemaker. The overall analysis showed a significantly increased risk of new 
PM implantation for TAVI compared to SAVR (p < 0.0001). The risk was increased both in RCTs 
(p = 0.007) and in Obs (p = 0.02) for TAVI (Fig. 4A). However, the comparisons were affected by 
high heterogeneity both in RCTs (I2 = 84%) and in Obs (I2 = 88%) (Fig. 4A). At the Funnel plot 2 
RCTs [5, 9] and 2 Obs [25, 27] fell outside the 95% CI (Fig. 4B). By excluding these studies, the 
sensitivity analysis confirmed a significant increase of the risk for new PM (p < 0.00001) with 
homogeneous results (Fig. 4A). 
Major, life threatening or disabling bleeding. Definitions of bleeding for each included 
study are reported in Table 2 of the supplemental material. VARC criteria were adopted by all the 
included studies with the only exclusion of Virtanen et al. [26]. This study, even though it was 
included in the initial analysis, was excluded in the sensitivity analysis because it was a source of 
heterogeneity (Table 4A).
The overall analysis showed a significant reduction of bleeding in TAVI compared to SAVR
(RR = –65%, p = 0.008); the analysis by subgroups showed in RCTs, was a significant risk 
reduction in favour of TAVI (RR = –71%, p = 0.002) whereas in Obs the reduction of bleeding in 
favor of TAVI was not significant (RR = –60%, p = 0.18; Fig. 4A). Indeed, the overall 
heterogeneity was extremely high (I2 = 92%) both in the RCTs (I2 = 84%) and in Obs (I2 = 92%) 
(Fig. 4A). After the sensitivity analysis, the comparisons were performed between more 
homogeneous populations (RCTs: I2 = 36%; Obs: I2 = 0%) and showed a significant reduction of 
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major bleeding for TAVI both in RCTs (p = 0.0004) and in Obs (p = 0.001) (Fig. 4A). Indeed, Obs 
and RCT had the same trend in the test for subgroup differences (Fig. 4A). 
Acute kidney injury stage 2 or 3. The overall analysis showed a non-significant reduction 
of acute kidney injury in TAVI compared to SAVR (RR = –40%, p = 0.51; Fig. 4A). In the analysis 
by subgroups, in RCTs (p = 0.0003), but not in Obs (p = 0.63), the risk of acute kidney injury was 
significantly reduced for TAVI (Fig. 4A). Indeed, RCTs were homogeneous (I2 = 0%), but the Obs 
were not (I2 = 96%), due to the study by Schaefer et al. [26] falling outside the 95% CI at the 
Funnel plot (Fig. 4B). By excluding the study by Schaefer et al. [25], a significant reduction of 
acute kidney injury was observed for TAVI (Fig. 4A). 
Stroke. The overall analysis showed a non-significant reduction of stroke in TAVI 
compared to SAVR (RR = –26%, p = 0.21; Fig. 5A). In the subgroups, the results of RCTs did not 
substantially differ from those of Obs: the risk of stroke was lower for TAVI, without reaching any 
statistically significant difference (Fig. 5A). 
Paravalvular leak. A significant increase of moderate/severe paravalvular leak for TAVI in 
the overall analysis was observed (p < 0.00001) both in RCTs (p = 0.0005) and in Obs (p = 0.001) 
(Fig. 5B). The results of the analysis of RCTs were in accordance with those of Obs (test for 
subgroup differences: Chi² = 0.01, df = 1, p = 0.92, I2 = 0%) (Fig. 5B).
DISCUSSION
The treatment of AS with TAVI in all patients in whom aortic valve surgery is indicated, 
irrespective of the surgical risk, is a useful goal to achieve because the interventional cardiology 
procedure is less invasive compared to cardiac surgery. Obviously, in order to extend the 
indications to TAVI in all patients with indications to SVAR, mostly in the low surgical risk, there 
must be conditions that allow it, and, in particular, the results of TAVI must be superimposable if 
not superior to those of surgical intervention [29, 30]. A major boost in this direction was given by 
the results of PARTNER 3 and EVOLUT LOW RISK trials, performed on patients with severe AS 
at low risk of death with surgery, which demonstrated the benefits of TAVI over surgery [9, 11]. 
Recently on the basis of RCTs [3–13] and registries [14, 24–28], TAVI was successfully reported in
patients with moderate and low surgical risk with comparable or even better results than SAVR. 
Due to the limited evidence coming from RCTs, the present meta-analysis also included available 
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evidence coming from Obs with the aim of increasing the power of analysis. However, the meta-
analysis was performed by the two subgroups in order to take into account separately the results 
coming from the two types of studies. The test for difference between RCTs and Obs was also 
computed to evaluate their agreement/disagreement. Indeed, as stated by Briere et al. [31], “the 
inclusion of real-world evidence in meta-analyses may facilitate the confirmation of conclusions 
drawn from randomized controlled trials and, thus, reassure decision-makers that findings can be 
extrapolated to real-world populations.” [31]. In the comparisons evaluating 30-day mortality, after 
the exclusion of the study by Schaefer et al. [25] according to the sensitivity analysis, the results of 
the meta-analysis with both RCTs and Obs were homogeneous (I2 = 0%) and superimposable and 
highlighted a significant 45% reduction in mortality in the patients undergoing TAVI (Fig. 2B). 
Indeed, the study by Schaefer et al. [25] was a source of heterogeneity not only in 30-day mortality 
but also in the analysis of many safety endpoints. As affirmed by Schaefer et al. [25]: “An 
important limitation of this study is that only first-generation devices were used in TAVI patients” 
and despite: “Baseline, procedural, and follow-up data were prospectively collected from dedicated
databases” data were “retrospectively analyzed”, having all the limitations of a retrospective study 
design [25].
In the present meta-analysis, at one year follow up, only the analysis of RCTs showed a 
significantly lower mortality in TAVI compared SAVR (p = 0.04), in disagreement with the results 
of the overall analysis, which nevertheless was affected by high heterogeneity in the test for 
subgroup differences (I2 = 65.1%) (Fig. 3).
As for the safety endpoints, the analysis did not demonstrate a different incidence of stroke 
between TAVI and SAVR (Fig. 5A). Furthermore, in TAVI a significantly increased risk of 
paravalvular leak (Fig. 5B) and new PM implantation (Fig. 4A) was observed (Fig. 5B). However, 
the analysis on new PM implantation was affected by high heterogeneity both in the overall effect 
(I2 = 83%) and into each subgroup (RCTs, I2 = 84%; Obs, I2 = 88%); Fig. 5A). As reported in the 
literature, this heterogeneity could be attributable to the inclusion of different types of prostheses in
the analysis (Table 1) [32, 33].
Limitations of the study
The analysis of Obs could overestimate the effect of the treatment, due to the lack of 
randomization [34, 35]. However, the results of Obs were in agreement with RCTs for most 
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comparisons, except when including the study of Schaefer et al. [25]. The reason was probably 
related (i) to the procedures performed in different intervals of time and (ii) to exclusive 
implantation of first-generation devices in TAVI (Table 1).
CONCLUSIONS
On the basis of the results of this meta-analysis TAVI is not superimposable to SAVR in 
patients with severe AS at low surgical risk. Some differences have to be highlighted. In particular, 
if 30-day and 1-year mortality, major/life threatening or disabling bleeding and acute kidney injury 
stage 2 or 3 were significantly lower for TAVI, the need of new PM implantation and perivalvular 
leak were significantly lower in SAVR. Indeed, these last two events do not always have an early 
prognostic impact, but their long-term implications have not yet been established.
Consequently, we suggest the need of more trials to evaluate the effectiveness of TAVI as 
routine therapeutic procedure in the treatment of patients with low surgical risk severe AS.
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Figure 1. Flow-chart of the study selection process; Obs — observational studies; RCTs — 
randomized controlled trials.
 
Figure 2. Forest plot of the primary end point: risk ratio (RR) of 30-day all-cause mortality 
between transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement 
12
(SAVR) in all studies (A) and after sensitivity analysis (B); CI — confidence interval; MH — 
Mantel-Haenszel; RCTs — randomized controlled trials.
Figure 3. Forest plot of the primary end point: risk ratio (RR) of 1-year all-cause mortality between
transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR); CI —
confidence interval; MH — Mantel-Haenszel; RCTs — randomized controlled trials.
Figure 4. 30-day safety endpoints: new permanent pacemaker implantation, major bleeding and 
acute kidney injury stage 2 or 3; A. Results of the comparisons  between transcatheter aortic valve 
implantation (TAVI) and surgical aortic valve replacement (SAVR) before and after the sensitivity 
analysis; B. Funnel plots on the log of risk ratio (RR) of each safety end-point, plotted against the 
standard error of the log RR; dotted lines represent the risk estimate and its 95% confidence limits; 
CI — confidence interval; MH — Mantel-Haenszel; NA — not applicable; Obs — observational 
studies; RCTs — randomized controlled trials.
Figure 5. Forest plots of the 30-day safety endpoints: risk ratio (RR) of stroke (A) and paravalvular
leak (B) between transcatheter aortic valve implantation (TAVI) and surgical aortic valve 
replacement (SAVR); RCTs — randomized controlled trials.
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Table 2. Bleeding criteria definition.




Tyregod et al., 2015
NOTION
VARC 2 No
Mack et al., 2019
PARTNER 3
VARC 2 Yes




Waksman et al., 2018
LRT Trial
VARC 2
(VARC 2 major bleeding for SAVR 
assumed if ≥ 3 units red blood cell 
transfusion given during procedure)
“Specific outcomes such as vascular 
complications and major or life-
threatening bleeding are not collected 
in the STS database either and 
No
15
therefore could not be compared. We 
therefore used the number of red blood 
cell transfusions as a surrogate for 
bleeding.”
Oh et al., 2019 VARC 2 No
Schaefer et al., 2019 VARC 2 Yes
Virtanen et al., 2019
FinnValve Registry 
“In this study, the Valvular Academic 
Research Consortium-2 definition of 
major and life-threatening bleeding 
was not applied because, unlike 
patients undergoing TAVR, a 
significant decrease of hemoglobin 
level is observed in most patients 
undergoing SAVR, and this does not 
always reflect a condition of major 
perioperative blood loss.”
Yes
SAVR — surgical aortic valve replacement; STS — Society of Thoracic Surgeons; 
TAVI — transcatheter aortic valve replacement; VARC 2 — Valvular Academic Research Consortium-2
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Full-text articles excluded (n = 5699)
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Reviews, Meta-analyses   921
Letter or Comment           486
Do not satisfy inclusion criteria  3708
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meta-analysis
(n = 9: 5 Obs, 4 RCTs)
(13 related articles) 
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Study RCTs  
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3)Popma, 2019 (EVOLUT LOW 
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eventsHeterogeneity: Tau² = 0.54; Chi² = 12.26, df = 4 (P = 0.02); I² 




eventsHeterogeneity: Tau² = 0.23; Chi² = 12.99, df = 7 (P = 0.07); I² 
= 46%Test for overall effect: Z = 1.61 (P = 
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1.88]0 42 [0.13, 
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2.30]0 57 [0.45, 
0.71]28 [0.03, 
3.01]3.56 [1.22, 
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(NOTION)Mack, 2019 (PARTNER 
3)Popma, 2019 (EVOLUT LOW 
RISK)Subtotal (95% 
CI)Total 
eventsHeterogeneity: Tau² = 0.00; Chi² = 0.18, df = 2 (P = 0.91); I² 
= 0%Test for overall effect: Z = 2.01 (P = 
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- RCTs 3 84  3.61 [1.43, 9.11] 0.007 1 NA 2.87 [2.05, 4.02]
<0.00
001
NOTION [5], PARTNER 3
[9]





Overall effect 7 83 3.53 [1.90, 6.55]
<0.00
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3 0 2.87 [2.01, 3.67]
<0.00
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